TY - JOUR
T1 - RTL therapy for multiple sclerosis
T2 - A Phase I clinical study
AU - Offner, Halina
AU - Sinha, Sushmita
AU - Burrows, Gregory G.
AU - Ferro, Adolph J.
AU - Vandenbark, Arthur A.
N1 - Funding Information:
This work was supported by the National Multiple Sclerosis Society Grants RG3794B, RG3794A and RG3468A , NIH Grants NS47661 , AI43960 , NS41965 , and NS46877 , and by the Biomedical Laboratory R&D Service, Department of Veterans Affairs . The authors wish to thank Ms. Eva Niehaus for assistance in preparing the manuscript and acknowledge the contributions of Chunhe Wang and Shayne Andrew. Dr. Offner, Dr. Burrows and Dr. Vandenbark have a significant financial interest in Artielle ImmunoTherapeutics, Inc., a company that may have a commercial interest in the result of this research and technology. This potential conflict of interest has been reviewed and managed by the OHSU and VAMC Conflict of Interest in Research Committees.
PY - 2011/2
Y1 - 2011/2
N2 - A human recombinant T cell receptor ligand (RTL1000) consisting of DR2 α1 and β1 domains linked covalently to MOG-35-55 peptide can reverse clinical and histological signs of experimental autoimmune encephalomyelitis (EAE), and was evaluated for safety in a Phase 1 randomized, placebo-controlled, escalating dose study in 34 subjects with multiple sclerosis (MS). RTL1000 was safe and well tolerated at a dose of ≤ 60. mg that is well within the effective dose range for EAE and did not cause worsening of MS disease at doses ≤ 200. mg. RTL1000 represents a novel approach for the treatment of MS that promises potent immunoregulation and CNS repair without global immunosuppression.
AB - A human recombinant T cell receptor ligand (RTL1000) consisting of DR2 α1 and β1 domains linked covalently to MOG-35-55 peptide can reverse clinical and histological signs of experimental autoimmune encephalomyelitis (EAE), and was evaluated for safety in a Phase 1 randomized, placebo-controlled, escalating dose study in 34 subjects with multiple sclerosis (MS). RTL1000 was safe and well tolerated at a dose of ≤ 60. mg that is well within the effective dose range for EAE and did not cause worsening of MS disease at doses ≤ 200. mg. RTL1000 represents a novel approach for the treatment of MS that promises potent immunoregulation and CNS repair without global immunosuppression.
KW - Clinical trial
KW - Experimental autoimmune encephalomyelitis (EAE)
KW - Multiple sclerosis (MS)
KW - Neuroprotection
KW - Recombinant T cell receptor ligand (RTL)
UR - http://www.scopus.com/inward/record.url?scp=79952441685&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79952441685&partnerID=8YFLogxK
U2 - 10.1016/j.jneuroim.2010.09.013
DO - 10.1016/j.jneuroim.2010.09.013
M3 - Article
C2 - 20965577
AN - SCOPUS:79952441685
SN - 0165-5728
VL - 231
SP - 7
EP - 14
JO - Journal of Neuroimmunology
JF - Journal of Neuroimmunology
IS - 1-2
ER -